172 related articles for article (PubMed ID: 2114789)
1. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
Oh T; Franko TG
Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789
[TBL] [Abstract][Full Text] [Related]
2. Experience with a two-tiered therapeutic interchange policy.
Rich DS
Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167
[TBL] [Abstract][Full Text] [Related]
3. Use of concurrent monitoring and a preprinted note to modify prescribing of i.v. cimetidine and ranitidine in a teaching hospital.
Dannenhoffer MA; Slaughter RL; Hunt SN
Am J Hosp Pharm; 1989 Aug; 46(8):1570-5. PubMed ID: 2773962
[TBL] [Abstract][Full Text] [Related]
4. An analysis of potential and real cost savings by the addition of ranitidine to total parenteral nutrition solutions.
Pearson VE; King LM
Hosp Pharm; 1992 Jul; 27(7):610, 613-4. PubMed ID: 10119189
[TBL] [Abstract][Full Text] [Related]
5. Use of i.v. cimetidine, ranitidine, and famotidine in 40 hospitals.
Segal R; Russell WL; Oh T; Ben-Joseph R
Am J Hosp Pharm; 1993 Oct; 50(10):2077-81. PubMed ID: 8238052
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive therapeutic interchange program in a community hospital.
Oh T; Franko TG
Am J Hosp Pharm; 1991 Jul; 48(7):1471-7. PubMed ID: 1882876
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of formulary restriction demonstrates significant cost savings.
Wetmore RW; Jennings RH
Hosp Formul; 1991 Nov; 26 Suppl D():30-2. PubMed ID: 10136564
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of the effect of omeprazole, cimetidine, famotidine and ranitidine on histamine induced cutaneous wheal and flare response.
Saha N; Sachdev A; Bhasin DK; Sankaranahyanan A; Khosla PP; Singh K; Sharma PL
Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):322-5. PubMed ID: 8103763
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic-interchange program for oral histamine H2-receptor antagonists.
Chase SL; Peterson AM; Wordell CJ
Am J Health Syst Pharm; 1998 Jul; 55(13):1382-6. PubMed ID: 9659966
[TBL] [Abstract][Full Text] [Related]
10. Comparison of famotidine with cimetidine and ranitidine.
Berardi RR; Tankanow RM; Nostrant TT
Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
[TBL] [Abstract][Full Text] [Related]
11. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
Quercia RA; Chow MS; Jay GT; Quintiliani R
Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
[TBL] [Abstract][Full Text] [Related]
12. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
Segal R; Oh T; Ben-Joseph R; Russell WL
Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
[TBL] [Abstract][Full Text] [Related]
13. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
Ohsawa T; Hirata W; Higichi S
Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
[TBL] [Abstract][Full Text] [Related]
14. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
Coppola P
Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
[TBL] [Abstract][Full Text] [Related]
15. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
[TBL] [Abstract][Full Text] [Related]
16. Effect of a criteria-based cost-containment program on the selection of oral H2-receptor antagonists.
Falbe WJ; Bess DT; Capers CC; Haymond JD; Stahl AA
Am J Hosp Pharm; 1992 Mar; 49(3):632-3. PubMed ID: 1598944
[No Abstract] [Full Text] [Related]
17. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
Slichenmyer WJ; Donehower RC; Chen TL; Bowling MK; McGuire WP; Rowinsky EK
Cancer Chemother Pharmacol; 1995; 36(3):227-32. PubMed ID: 7781143
[TBL] [Abstract][Full Text] [Related]
18. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
Kitrenos JG; Brown DR; Letting DJ; Rotella DL
Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
[TBL] [Abstract][Full Text] [Related]
19. The clinical use of histamine-2 receptor antagonists.
Michocki RJ; Richardson JP
Md Med J; 1992 May; 41(5):397-400. PubMed ID: 1625532
[TBL] [Abstract][Full Text] [Related]
20. Restoration of bactericidal activity of peritoneal fluid by cimetidine but not ranitidine or famotidine in burned mice.
Altaca G; Sayek I; Onat D; Gür D; Akalin E
Eur J Surg; 1993 Oct; 159(10):551-4. PubMed ID: 8286513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
